Professor Gareth Griffiths, Director of the SCTU Professor Gareth Griffiths, Director of the Cancer Research UK Southampton Scientific Trial System (SCTU) at the University of Southampton’s Centre for Cancer Immunology, stated:”Cancer vaccines have the potential to enhance the method we deal with the illness, particularly for those cancers where treatment alternatives are presently restricted or extremely demanding on patients’ bodies. Although there have been some trials of cancer vaccine prospects in the past, there are a brand-new generation of vaccines that are personalised to specific biological functions of a patient’s disease.
“We are thrilled to have been selected to run the national platform which will unite a number of vaccine trials so that clients can access these trials more easily, enhancing our research knowledge and ideally leading to improved treatment results for clients.”
Peter Johnson, Professor of Medical Oncology at the University of Southampton and NHS National Medical Director for Cancer, said: “We know that even after an effective operation, cancers can sometimes return because a few cancer cells are left in the body, but utilizing a vaccine to target those remaining cells might be a method to stop this taking place. Access to clinical trials could offer another choice for clients and their households, and I’m pleased that through our nationwide launch pad we will be widening the chances to be part of these trials for much more people.”
The NHS Cancer Vaccine Launch Pad
Trials readily available through the CVLP will each be testing a new investigational cancer vaccine.
Dr Victoria Goss, Head of Early Diagnosis and Translational Research at the SCTU, said: “Clients with early or late-stage cancer who are getting cancer treatment on the NHS will be able to have actually tumour samples sent to the labs for analysis. If their cancer contains anomalies that might appropriate for use in a personalised cancer vaccine, then they may be eligible to get in screening for one of the vaccine trials.”
Dr Victoria Goss, Head of Early Medical Diagnosis & Translational Research
The very first trial offered through the CVLP is evaluating a vaccine under development by biotech business BioNTech SE, for a type of colorectal cancer. More vaccines targeting other cancer types will be presented as the CVLP expands.
The SCTU is a world-leading Cancer Research study UK trials unit with know-how in running complex cancer immunotherapy trials and coordinating large-scale platform trials.
SCTU Clinical Director Professor Simon Crabb stated: “We have a history of undertaking cancer trials in numerous kinds of immunotherapies, including cancer vaccines. The Cancer Vaccine Launch Pad will bring together different scholastic and market partners who are establishing cancer vaccines and permit patients across England to access trials of treatments that might not have actually previously been an option for them.”
Becoming part of a cancer vaccine trial
Ali Richards, 63, from Poole in Dorset, took part in a previous cancer vaccine trial at SCTU after her head and neck cancer returned following initial treatment.
She said: “After medical diagnosis in 2016, I had radiotherapy and chemotherapy treatment. The treatment was truly brutal and left me struggling to swallow and requiring to be fed through a tube in my stomach. Regrettably, it was not completely effective and in 2017 I had surgery to eliminate some lymph nodes in my neck which set my recovery back once again.”
Ali Richards reduced weight as a result of her treatment
Ali then participated in a scientific trial of an investigational cancer vaccine.
She discussed: “My oncologist’s factor for recommending the trial was that it could perhaps assist my resistance going forward and help protect me. For me, I wanted to do it due to the fact that I thought if it might assist other individuals not to go through what I ‘d just been through, if there was potentially something that was going to be alleviative or improve their resistance in some way, then would not that be dazzling.
“It’s truly essential that we speed up progress in cancer vaccine trials. Conventional treatments are not kind by their nature, and anything that can make treatment more simple, more reliable, less intrusive, has actually got to be a good idea.
“Cancer is terrible, any type of cancer. Coping with the fear that cancer might return is not great. If we might free people from that concern and concern, that would be a remarkable thing to happen.”
Seeking to the future
The very first trial offered through the CVLP is now hiring patients with colorectal cancer at a variety of healthcare facilities throughout England.
Dr Goss outlined: “Over the coming months, more healthcare facility websites will sign up with the CVLP platform permitting more patients to access investigational cancer vaccines trials.”
Teacher Griffiths concluded: “Research study and scientific trials are vital for improving how we deal with cancer and assisting to improve results for clients. By uniting the most innovative immunotherapies and personalised treatment trials through the Cancer Vaccine Release Pad we wish to facilitate more client access to these scientific trials and ultimately speed up the development in cancer treatments.”